Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-aminolevulinic acid + OJP-001
- Development stage
- Unknown
- Lead developer
- JIMRO
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral (5-ALA), Extracorporeal Photodynamic Application (OJP-001 Device)
01
Overview
**5-aminolevulinic acid + OJP-001** is a combination therapeutic system used primarily as an investigational treatment for adult T-cell leukemia/lymphoma. The regimen consists of oral administration of 5-aminolevulinic acid (5-ALA), a small molecule precursor in the heme biosynthetic pathway, followed by use of OJP-001, a photodynamic therapy (PDT) system. After 5-ALA administration, the photodynamic system activates accumulated protoporphyrin IX (PpIX) in cancerous cells via specific light exposure, leading to cellular destruction through the generation of reactive oxygen species[4]. OJP-001 integrates photodynamic therapy with extracorporeal circulation technology as a novel approach to target circulating malignant cells[3][4]. The mechanism leverages 5-ALA's selective accumulation and conversion to PpIX in malignant cells, enhancing the effectiveness and specificity of PDT for hematologic malignancies.
- Other names
- 5-ALA + OJP-0015-aminolevulinic acid + OJP-001
Beyond the preview
Go deeper on 5-aminolevulinic acid + OJP-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-aminolevulinic acid + OJP-001.